MedPath

Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism

Not Applicable
Withdrawn
Conditions
Non Obstructive Azoospermia
Hypogonadism
Interventions
Drug: Placebo
Registration Number
NCT02137265
Lead Sponsor
University of Illinois at Chicago
Brief Summary

Hypothesis: Prescribed clomiphene citrate to azoospermic patients with hypoandrogenism could improve the sperm retrieval in either fresh sperm or after surgical sperm extraction.

Detailed Description

Hypogonadism (low testosterone level) is frequently observed in men presenting with non obstructive azoospermia. Controversy exists regarding the efficacy of preoperative hormonal manipulation in patients with hypogonadism. However, it is possible that hormonal therapy increases intra-testicular testosterone levels, and with a rise in serum testosterone, sperm production and surgical success with microTESE improve.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Male
Target Recruitment
Not specified
Inclusion Criteria
  • Patients over 18 years old.
  • Man seeking fertility treatment.
  • Azoospermia confirmed in at least 2 semen analyses with centrifugation.
  • Testosterone <300 ng/dL and Bioavailable Testosterone<156 ng/dL.
Exclusion Criteria
  • Presence of genetic disorders: Y chromosome deletions or abnormal karyotypes.
  • Luteinizing hormone (LH) >25 IU/mL.
  • Estradiol > 40 ng/dL.
  • Hypogonadotropic hypogonadism (LH <2 IU/mL and Follicle Stimulating Hormone (FSH) <1 IU/mL).
  • Obstructive azoospermia (FSH <7.6 IU/mL plus testicle longitudinally axis >4.6 cm or bilateral absence of vas deferens or surgical history of vasectomy).
  • Clinical varicocele (palpable or visible in physical exam)
  • Previous history of cryptorchidism.
  • Use of chemotherapy, testosterone, or anti-androgen in the last two years. Partner >40 years or female factor infertility associated.
  • Contraindications to clomiphene use: depression, heart and liver impairment, uncontrolled thyroid/adrenal dysfunction, organic intracranial lesions.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo (1 pill daily) during 4-6 months
Clomiphene citrateClomipheneClomiphene citrate 50 mg daily during 4-6 months
Primary Outcome Measures
NameTimeMethod
Presence of sperm in the ejaculated or in the microsurgical testicular Sperm extraction (microTESE)After four months of clomiphene treatment
Epigenetic modificationsAfter four months of clomiphene treatment
Secondary Outcome Measures
NameTimeMethod
Testosterone levels and Bioavailable Testosterone levelsAfter two weeks and four months with clomiphene treatment

Trial Locations

Locations (1)

University of Valencia

🇪🇸

Valencia, Province Of Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath